Greg Jennings LLC Acquires 3,279 Shares of Quest Diagnostics Incorporated $DGX

Greg Jennings LLC purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX) in the third quarter, HoldingsChannel reports. The institutional investor purchased 3,279 shares of the medical research company’s stock, valued at approximately $764,000.

Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Quest Diagnostics in the 2nd quarter valued at $1,965,923,000. Bank of America Corp DE purchased a new stake in Quest Diagnostics during the 2nd quarter valued at about $410,151,000. Legal & General Group Plc acquired a new position in Quest Diagnostics during the second quarter worth $151,986,000. Bank of New York Mellon Corp acquired a new position in shares of Quest Diagnostics during the 2nd quarter valued at about $133,388,000. Finally, Deutsche Bank AG acquired a new position in Quest Diagnostics in the second quarter valued at approximately $124,180,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on DGX shares. Robert W. Baird lifted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Jefferies Financial Group restated a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a report on Thursday, July 23rd. JPMorgan Chase & Co. lifted their target price on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research report on Tuesday, July 28th. Argus set a $260.00 target price on Quest Diagnostics in a research report on Wednesday, July 29th. Finally, UBS Group reiterated a “neutral” rating and set a $250.00 price target on shares of Quest Diagnostics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $238.23.

Quest Diagnostics Stock Down 0.0%

Shares of NYSE:DGX traded down $0.08 during trading on Monday, hitting $234.92. The company’s stock had a trading volume of 864,589 shares, compared to its average volume of 977,358. Quest Diagnostics Incorporated has a fifty-two week low of $171.18 and a fifty-two week high of $248.84. The business has a 50 day moving average price of $237.40 and a two-hundred day moving average price of $215.48. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. The company has a market capitalization of $25.93 billion, a PE ratio of 24.94, a P/E/G ratio of 2.13 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, research analysts expect that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be given a $0.86 dividend. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.52%.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Michael Prevoznik sold 22,677 shares of Quest Diagnostics stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $243.11, for a total value of $5,513,005.47. Following the completion of the transaction, the senior vice president owned 37,557 shares in the company, valued at approximately $9,130,482.27. This trade represents a 37.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark Delaney sold 1,600 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the transaction, the senior vice president owned 10,335 shares of the company’s stock, valued at $2,430,585.30. This trade represents a 13.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 34,277 shares of company stock valued at $8,316,493 in the last quarter. Corporate insiders own 0.88% of the company’s stock.

Quest Diagnostics Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.